3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
160
Leukemia, Myeloid, Acute
123
Leukemia, Myelomonocytic, Chronic
65
Leukemia
35
Myeloproliferative Disorders
23
Primary Myelofibrosis
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Anemia, Refractory, with Excess of Blasts
11
Hematologic Neoplasms
10
Myelodysplastic-Myeloproliferative Diseases
9
Recurrence
8
Multiple Myeloma
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
7
Lymphoma, Non-Hodgkin
6
Leukemia, Biphenotypic, Acute
6
Lymphoma
5
Polycythemia Vera
4
Leukemia, Myelomonocytic, Juvenile
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia, Erythroblastic, Acute
4
Hematologic Diseases
4
Anemia, Refractory
4
Thrombocythemia, Essential
3
Prostatic Neoplasms
3
Neoplasm, Residual
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Interventions
avapritinib
5
midostaurin
4
masitinib
2
Imatinib Mesylate
2
sarilumab
1
ripretinib
1
obatoclax
1
nilotinib
1
ibrutinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
denileukin diftitox
1
auricularum
1
Thalidomide
1
Ranitidine
1
Phlebotomy
1
Interviews as Topic
1
Ibuprofen
1
Everolimus
1
Diphenhydramine
1
Dexamethasone
1
Denosumab
1
Dasatinib
1
Cladribine
1
Calcium Dobesilate
1
Brentuximab Vedotin
1
Azacitidine
1
Acetaminophen
1
AK002
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mastocytosis, Systemic
×
Azacitidine
×
Myeloid
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled